SCHEMBL29946174

SCHEMBL29946174

C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)CCl

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CASP1 P29466 18/20 0.56
▸ CTSK P43235 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9901045 1.00 CASP1 (0.56) CASP1CTSK
SCHEMBL9925821 0.91 CTSK (0.52) CASP1CTSK
SCHEMBL29397437 0.91 REN (0.55) CASP1CTSK
SCHEMBL15485852 0.89 CTSK (0.52) CASP1CTSK
SCHEMBL29825423 0.89 CASP3 (0.60) CASP1CTSK
SCHEMBL29453232 0.88 MME (0.58) CASP1CTSK
SCHEMBL19067195 0.87 CASP1 (0.57) CASP1CTSK
SCHEMBL7155003 0.87 MME (0.59) CASP1CTSK
SCHEMBL4430771 0.87 MME (0.59) CASP1CTSK
SCHEMBL14433707 0.87 MME (0.59) CASP1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-05-08 — — US disclosed
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-04-17 — — US disclosed
US-12139744-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2024-11-12 — — US disclosed
US-12110533-B2 Stabilisation and isolation of extracellular nucleic acids QIAGEN GMBH (DE) 2024-10-08 — — US disclosed
US-20240268372-A1 Methods and Compositions for Extending Organ and Tissue Preservation MASSACHUSETTS GEN HOSPITAL (US) 2024-08-15 — — US disclosed
EP-4397770-A1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PreAnalytiX GmbH (CH) 2024-07-10 — — EP disclosed
US-11525155-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2022-12-13 — — US disclosed
US-20220364149-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2022-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 CASP1 1854/4885CTSK 434/4885
US-12139744-B2 Stabilisation of biological samples RNASE1, RNASEH1, EWSR1 CASP1 1854/4885CTSK 434/4885
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 CASP1 1854/4885CTSK 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback